Serum prostate-specific antigen testing is the primary method for screening and early detection of prostate cancer. This testing is known for its sensitivity but is limited by low specificity. Elevated levels of prostate-specific antigen can result from benign conditions, leading to potential overdiagnosis and unnecessary biopsies, which strain healthcare resources. Risk stratification biomarkers are designed for lower-risk and borderline patients, typically with prostate-specific antigen levels between 4 and 10 ng/mL. If test results are negative, these biomarkers help avoid further invasive diagnostics, thus reducing unnecessary procedures. However, for high-risk patients, biopsies remain necessary regardless of biomarker results.Current and investigational biomarkers, including blood- and urine-based assays, improve diagnostic accuracy by supplementing prostate-specific antigen testing. Each biomarker offers unique advantages in detecting, diagnosing, and monitoring prostate cancer, often integrated into risk assessment tools for better clinical decision-making. Ideal biomarkers are highly sensitive and specific, easy to use, cost-effective, and approved by relevant health authorities, enhancing their use in clinical practice. This activity for healthcare professionals is designed to enhance the learner’s understanding of the available risk-stratification biomarkers and those currently investigating to ensure early and accurate detection of prostate cancer and improve patient outcomes.
- Provider:StatPearls, LLC
- Activity Link: https://www.statpearls.com/ArticleLibrary/viewarticle/144254
- Start Date: 2023-09-01 05:00:00
- End Date: 2023-09-01 05:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours
Pharmacy: 1.0 hours - MOC Credit Details: ABS - 1.0 Point; Credit Type(s): Accredited CME (ABS)
ABPATH - 1.0 Point; Credit Type(s): Lifelong Learning (ABPATH)
ABA - 1.0 Point; Credit Type(s): Lifelong Learning (ABA)
ABIM - 1.0 Point; Credit Type(s): Medical Knowledge (ABIM)
ABS - 1.0 Point; Credit Type(s): Self-Assessment (ABS) - Commercial Support: No
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: Variable
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: Ambulatory/Outpatient, Chemical Pathology, Complex General Surgical Oncology, General Operative Anesthesia, Geriatric Medicine, Hospice and Palliative Medicine, Hospital Medicine, Internal Medicine, Medical Oncology, Molecular Genetic Pathology